BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 31177425)

  • 21. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
    Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
    Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteins involved in regulating bone invasion in skull base meningiomas.
    Salehi F; Jalali S; Alkins R; Lee JI; Lwu S; Burrell K; Gentili F; Croul S; Zadeh G
    Acta Neurochir (Wien); 2013 Mar; 155(3):421-7. PubMed ID: 23238945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas.
    Tang H; Zhu H; Wang X; Hua L; Li J; Xie Q; Chen X; Zhang T; Gong Y
    J Mol Cell Biol; 2017 Aug; 9(4):315-324. PubMed ID: 28651379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development.
    Najm P; Zhao P; Steklov M; Sewduth RN; Baietti MF; Pandolfi S; Criem N; Lechat B; Maia TM; Van Haver D; Corthout N; Eyckerman S; Impens F; Sablina AA
    Cancer Res; 2021 Aug; 81(16):4218-4229. PubMed ID: 34215617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NF2 status of meningiomas is associated with tumour localization and histology.
    Kros J; de Greve K; van Tilborg A; Hop W; Pieterman H; Avezaat C; Lekanne Dit Deprez R; Zwarthoff E
    J Pathol; 2001 Jul; 194(3):367-72. PubMed ID: 11439370
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Kaidonis G; Pekmezci M; Van Ziffle J; Auguste KI; Horton JC
    J Neurosurg Case Lessons; 2022 Jun; 3(23):CASE2247. PubMed ID: 35733823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
    Clark VE; Harmancı AS; Bai H; Youngblood MW; Lee TI; Baranoski JF; Ercan-Sencicek AG; Abraham BJ; Weintraub AS; Hnisz D; Simon M; Krischek B; Erson-Omay EZ; Henegariu O; Carrión-Grant G; Mishra-Gorur K; Durán D; Goldmann JE; Schramm J; Goldbrunner R; Piepmeier JM; Vortmeyer AO; Günel JM; Bilgüvar K; Yasuno K; Young RA; Günel M
    Nat Genet; 2016 Oct; 48(10):1253-9. PubMed ID: 27548314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 expression in meningiomas.
    Johnson MD
    J Clin Neurosci; 2018 Nov; 57():149-151. PubMed ID: 30153998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
    Han SJ; Reis G; Kohanbash G; Shrivastav S; Magill ST; Molinaro AM; McDermott MW; Theodosopoulos PV; Aghi MK; Berger MS; Butowski NA; Barani I; Phillips JJ; Perry A; Okada H
    J Neurooncol; 2016 Dec; 130(3):543-552. PubMed ID: 27624915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma.
    Maiuri F; Mariniello G; Guadagno E; Barbato M; Corvino S; Del Basso De Caro M
    Acta Neurochir (Wien); 2019 Dec; 161(12):2553-2561. PubMed ID: 31637512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
    Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
    Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges.
    Fountain DM; Smith MJ; O'Leary C; Pathmanaban ON; Roncaroli F; Bobola N; King AT; Evans DG
    Oncogene; 2021 Feb; 40(5):875-884. PubMed ID: 33262459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
    Brastianos PK; Horowitz PM; Santagata S; Jones RT; McKenna A; Getz G; Ligon KL; Palescandolo E; Van Hummelen P; Ducar MD; Raza A; Sunkavalli A; Macconaill LE; Stemmer-Rachamimov AO; Louis DN; Hahn WC; Dunn IF; Beroukhim R
    Nat Genet; 2013 Mar; 45(3):285-9. PubMed ID: 23334667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity.
    Zador Z; Landry AP; Balas M; Cusimano MD
    Sci Rep; 2020 Jun; 10(1):9065. PubMed ID: 32493984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies.
    Hashimoto N; Rabo CS; Okita Y; Kinoshita M; Kagawa N; Fujimoto Y; Morii E; Kishima H; Maruno M; Kato A; Yoshimine T
    J Neurosurg; 2012 Mar; 116(3):574-80. PubMed ID: 22175721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas.
    Schieffer KM; Agarwal V; LaHaye S; Miller KE; Koboldt DC; Lichtenberg T; Leraas K; Brennan P; Kelly BJ; Crist E; Rusin J; Finlay JL; Osorio DS; Sribnick EA; Leonard JR; Feldman A; Orr BA; Serrano J; Vasudevaraja V; Snuderl M; White P; Magrini V; Wilson RK; Mardis ER; Boué DR; Cottrell CE
    Am J Surg Pathol; 2021 Mar; 45(3):329-340. PubMed ID: 33074854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Characteristics and Magnetic Resonance Imaging-Based Prediction of the KLF4
    von Spreckelsen N; Waldt N; Timmer M; Goertz L; Reinecke D; Laukamp K; Pennig L; Grau S; Deckert M; Kirches E; Stavrinou P; Mawrin C; Goldbrunner R
    World Neurosurg; 2021 Oct; 154():e665-e670. PubMed ID: 34343686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease.
    Mishra-Gorur K; Barak T; Kaulen LD; Henegariu O; Jin SC; Aguilera SM; Yalbir E; Goles G; Nishimura S; Miyagishima D; Djenoune L; Altinok S; Rai DK; Viviano S; Prendergast A; Zerillo C; Ozcan K; Baran B; Sencar L; Goc N; Yarman Y; Ercan-Sencicek AG; Bilguvar K; Lifton RP; Moliterno J; Louvi A; Yuan S; Deniz E; Brueckner M; Gunel M
    Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2214997120. PubMed ID: 37043537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.